Therefore, double positive for CD43 and CD180, together with other B‐cell surface markers could improve the sensitivity of the diagnosis in CLL patients with negative expression of CD5 or CD23. This evidence concerns the gene CD5 and B-cell chronic lymphocytic leukemia.